Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP3 | P15309 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.42 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.42 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | POLQ | O75417 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5156128 | 1.00 | ACP3 (0.51) | ACP3CNR2LMNAMAPK1PPARG | |
| SCHEMBL6679044 | 1.00 | ACP3 (0.51) | ACP3CNR2LMNAMAPK1PPARG | |
| SCHEMBL6680423 | 0.84 | ACP3 (0.41) | ACP3CNR2LMNAMAPK1PPARG | |
| SCHEMBL6676317 | 0.84 | ACP3 (0.41) | ACP3CNR2LMNAMAPK1PPARG | |
| SCHEMBL6676308 | 0.84 | ACP3 (0.41) | ACP3CNR2LMNAMAPK1PPARG | |
| SCHEMBL23972302 | 0.84 | IDO1 (0.48) | ACP3CNR2LMNAMAPK1PPARG | |
| SCHEMBL7472384 | 0.83 | ACP3 (0.46) | ACP3CNR2LMNACACNA2D1CACNA1B | |
| SCHEMBL3130946 | 0.82 | ACP3 (0.53) | ACP3CNR2LMNAPPARGCACNA2D1 | |
| SCHEMBL28821897 | 0.82 | ACP3 (0.53) | ACP3CNR2LMNAPPARGCACNA2D1 | |
| SCHEMBL23972340 | 0.82 | TAS2R14 (0.46) | ACP3CNR2LMNAMAPK1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339934-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2023-10-26 | — | — | US | disclosed |
| US-20230339934-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2023-10-26 | — | — | US | disclosed |
| CN-109689667-B | Porous chiral material and use thereof | 南开大学 | 2022-07-12 | — | — | CN | disclosed |
| WO-2021221169-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2021-11-04 | — | — | WO | disclosed |
| US-10857517-B2 | Porous chiral materials and uses thereof | NANKAI UNIVERSITY (CN) | 2020-12-08 | — | — | US | disclosed |
| CN-109689667-A | Porous chiral material and use thereof | 南开大学 | 2019-04-26 | — | — | CN | disclosed |
| EP-2688554-A2 | OPTIMISED PREPARATIONS OF HIGHLY ADAPTABLE AGGREGATES | Cevc, Gregor (DE) | 2014-01-29 | — | — | EP | disclosed |
| US-20140017302-A1 | OPTIMISED PREPARATIONS OF HIGHLY ADAPTABLE AGGREGATES | CEVC GREGOR (DE) | 2014-01-16 | — | — | US | disclosed |
| WO-2012126966-A2 | OPTIMISED PREPARATIONS OF HIGHLY ADAPTABLE AGGREGATES | CEVC GREGOR (DE) | 2012-09-27 | — | — | WO | disclosed |
| US-8138272-B2 | Preparation of polymer conjugates of therapeutic, agricultural, and food additive compounds | ELAN PHARMACEUTICALS, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-6124343-A | Substituted phenyl compounds with a substituent having a thienyl ring | RHONE-POULENC RORER LIMITED (GB) | 2000-09-26 | — | — | US | disclosed |
| EP-0805802-B1 | SUBSTITUTED PHENYL COMPOUNDS AS ENDOTHELIN ANTAGONISTS | RHONE POULENC RORER LTD (GB) | 2000-08-16 | — | — | EP | disclosed |
| US-6048893-A | Substituted phenyl compounds with a substituent having A 1,3-benzodioxole ring | RHONE-POULENC RORER LIMITED (GB) | 2000-04-11 | — | — | US | disclosed |
| WO-1999059587-A1 | ANTI-VIRAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-11-25 | — | — | WO | disclosed |
| EP-0805802-A1 | SUBSTITUTED PHENYL COMPOUNDS AS ENDOTHELIN ANTAGONISTS | RHONE-POULENC RORER LIMITED (GB) | 1997-11-12 | — | — | EP | disclosed |
| WO-1996022978-A1 | SUBSTITUTED PHENYL COMPOUNDS AS ENDOTHELIN ANTAGONISTS | RHONE POULENC RORER LIMITED (GB) | 1996-08-01 | — | — | WO | disclosed |
| US-4297489-A | CEPHALOSPORINS | BRISTOL-MYERS COMPANY (US) | 1981-10-27 | — | — | US | disclosed |
| US-4172196-A | CEPHALOSPORINS | BRISTOL-MYERS COMPANY (US) | 1979-10-23 | — | — | US | disclosed |
| US-4112228-A | BACTERICIDES | BRISTOL-MYERS COMPANY (US) | 1978-09-05 | — | — | US | disclosed |
| US-3985738-A | ANTIBACTERIAL AGENTS | BRISTOL-MYERS COMPANY (US) | 1976-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140017302-A1 | OPTIMISED PREPARATIONS OF HIGHLY ADAPTABLE AGGREGATES | CD68, CHMP4B, ANXA5 | ACP3 1228/4885CNR2 4106/4885LMNA 1510/4885 |
| US-20230339934-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | TRPV4, TRPV1, TRPV2 | ACP3 846/4885CNR2 124/4885LMNA 4199/4885 |
| US-10857517-B2 | Porous chiral materials and uses thereof | ANXA7, XDH, OPRM1 | ACP3 2224/4885CNR2 1162/4885LMNA 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.